Armida Mucci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5361131/publications.pdf

Version: 2024-02-01

61984 79698 6,291 171 43 73 citations h-index g-index papers 195 195 195 6268 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study. Psychological Medicine, 2023, 53, 3471-3479.	4.5	6
2	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. Frontiers in Psychiatry, 2022, 13, 826465.	2.6	13
3	Joint structural-functional magnetic resonance imaging features are associated with diagnosis and real-world functioning in patients with schizophrenia. Schizophrenia Research, 2022, 240, 193-203.	2.0	4
4	The Cognitive Assessment Interview (CAI): Association with neuropsychological scores and real-life functioning in a large sample of Italian subjects with schizophrenia. Schizophrenia Research, 2022, 241, 161-170.	2.0	5
5	Negative Symptom Domains in Children and Adolescents at Ultra-High Risk for Psychosis: Association With Real-Life Functioning. Schizophrenia Bulletin Open, 2022, 3, .	1.7	4
6	Scalability of the Positive and Negative Syndrome Scale in firstâ€episode schizophrenia assessed by Rasch models. Acta Psychiatrica Scandinavica, 2022, 146, 21-35.	4.5	4
7	Special Report on the Impact of the COVID-19 Pandemic on Clinical EEG and Research and Consensus Recommendations for the Safe Use of EEG. Clinical EEG and Neuroscience, 2021, 52, 3-28.	1.7	13
8	Can IQ moderate the response to cognitive remediation in people with schizophrenia?. Journal of Psychiatric Research, 2021, 133, 38-45.	3.1	12
9	Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study. Schizophrenia Bulletin, 2021, 47, 444-455.	4.3	9
10	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. European Psychiatry, 2021, 64, e7.	0.2	15
11	EPA guidance on treatment of negative symptoms in schizophrenia. European Psychiatry, 2021, 64, e21.	0.2	70
12	Autism Rating Scale: A New Tool for Characterizing the Schizophrenia Phenotype. Frontiers in Psychiatry, 2021, 12, 622359.	2.6	7
13	Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. Schizophrenia Research, 2021, 228, 29-35.	2.0	11
14	P.307 Resting state MRI functional connectivity and negative symptoms in subjects with schizophrenia. European Neuropsychopharmacology, 2021, 44, S44-S45.	0.7	0
15	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. JAMA Psychiatry, 2021, 78, 550.	11.0	89
16	EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review. Frontiers in Psychiatry, 2021, 12, 653642.	2.6	44
17	EPA guidance on assessment of negative symptoms in schizophrenia. European Psychiatry, 2021, 64, e23.	0.2	94
18	P.0589 Resting-state functional connectivity of the ventral tegmental area and negative symptoms in subjects with schizophrenia: a resting-state functional MRI study. European Neuropsychopharmacology, 2021, 53, S431-S432.	0.7	0

#	Article	IF	CITATIONS
19	Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia. Brain Sciences, 2021, 11, 1632.	2.3	12
20	Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review. Frontiers in Psychiatry, 2021, 12, 789179.	2.6	35
21	P.0592 Investigating the relationships of N100-P3b with symptom dimensions and cognitive impairments in subjects with chronic schizophrenia. European Neuropsychopharmacology, 2021, 53, S432-S433.	0.7	0
22	The interplay among psychopathology, personal resources, contextâ€related factors and realâ€life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and nonâ€recovered patients. World Psychiatry, 2020, 19, 81-91.	10.4	96
23	P.778 Electrophysiological indices and expressive deficit domain of negative symptoms in subjects with schizophrenia. European Neuropsychopharmacology, 2020, 40, S442.	0.7	0
24	P.779 Multivariate investigations of electrophysiological indices for the diagnosis and prognosis of schizophrenia. European Neuropsychopharmacology, 2020, 40, S442-S443.	0.7	0
25	Treating Schizophrenia: Open Conversations and Stronger Relationships Through Psychoeducation and Shared Decision-Making. Frontiers in Psychiatry, 2020, 11, 761.	2.6	9
26	Abnormal bodily experiences detected by Abnormal Bodily Phenomena questionnaire are more frequent and severe in schizophrenia than in bipolar disorder with psychotic features. European Psychiatry, 2020, 63, e49.	0.2	5
27	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia – data from the OPTiMiSE trial. Psychiatry Research, 2020, 289, 112970.	3.3	11
28	Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques. Frontiers in Neuroscience, 2020, 14, 632.	2.8	17
29	Schizophrenia and "unmet needs― From diagnosis to care in Italy. European Psychiatry, 2020, 63, e26.	0.2	9
30	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. European Neuropsychopharmacology, 2020, 34, 76-86.	0.7	30
31	Neurobiology of Schizophrenia: Electrophysiological Indices. , 2019, , 433-459.		2
32	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. European Neuropsychopharmacology, 2019, 29, 947-959.	0.7	60
33	Neuroimaging and Psychopathological Domains. , 2019, , 57-155.		3
34	White matter structural connectivity abnormalities in subjects with deficit schizophrenia: A diffusion tensor imaging study. European Neuropsychopharmacology, 2019, 29, S110.	0.7	0
35	17.2 NEGATIVE SYMPTOMS IN THE OPTIMISE COHORT: PREDICTION OF SHORT-TERM REMISSION STATE AND ASSOCIATION WITH PSYCHOSOCIAL FUNCTIONING. Schizophrenia Bulletin, 2019, 45, S116-S116.	4.3	0
36	Academic and social functioning in early life epochs in schizophrenia patients and first-degree unaffected relatives. European Neuropsychopharmacology, 2019, 29, S336.	0.7	0

#	Article	IF	Citations
37	A feasibility, acceptability and validation study of the Italian Version of a new cognitive remediation program for psychotic patients – CIRCuiTS. European Neuropsychopharmacology, 2019, 29, S318-S319.	0.7	O
38	Disorganization and cognitive impairment in schizophrenia: New insights from electrophysiological findings. International Journal of Psychophysiology, 2019, 145, 99-108.	1.0	23
39	<p>The Efficacy, Feasibility And Acceptability Of A Remotely Accessible Use Of CIRCuiTS, A Computerized Cognitive Remediation Therapy Program For Schizophrenia: A Pilot Study</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 3103-3113.	2.2	6
40	Network Analysis Reveals the Latent Structure of Negative Symptoms in Schizophrenia. Schizophrenia Bulletin, 2019, 45, 1033-1041.	4.3	88
41	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. World Journal of Biological Psychiatry, 2019, 20, 126-136.	2.6	12
42	Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. Schizophrenia Bulletin, 2019, 45, 305-314.	4.3	99
43	Functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia: a resting state functional MRI study. European Neuropsychopharmacology, 2018, 28, 589-602.	0.7	32
44	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. JAMA Psychiatry, 2018, 75, 396.	11.0	214
45	Electrophysiological and Neuroimaging Research on Negative Symptoms: Future Challenges. Clinical EEG and Neuroscience, 2018, 49, 3-5.	1.7	1
46	Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry,the, 2018, 5, 664-677.	7.4	316
47	Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. Psychological Medicine, 2018, 48, 1359-1366.	4.5	37
48	Avolition-Apathy and White Matter Connectivity in Schizophrenia: Reduced Fractional Anisotropy Between Amygdala and Insular Cortex. Clinical EEG and Neuroscience, 2018, 49, 55-65.	1.7	31
49	Impact of Reward and Loss Anticipation on Cognitive Control: An Event-Related Potential Study in Subjects With Schizophrenia and Healthy Controls. Clinical EEG and Neuroscience, 2018, 49, 46-54.	1.7	8
50	T206. DOES AGE INFLUENCE RESPONSE TO COGNITIVE REMEDIATION?. Schizophrenia Bulletin, 2018, 44, S196-S197.	4.3	0
51	F114. DISORGANIZATION AND COGNITIVE DYSFUNCTIONS IN SCHIZOPHRENIA: A STUDY OF RESTING STATE EEG. Schizophrenia Bulletin, 2018, 44, S264-S264.	4.3	0
52	Experimental and Theoretical Investigation of Intercalation and Molecular Structure of Organo-Iron Complexes in Montmorillonite. Journal of Physical Chemistry C, 2018, 122, 25422-25432.	3.1	11
53	Acute Effects of Music Therapy in Subjects With Psychosis During Inpatient Treatment. Psychiatry (New York), 2018, 81, 218-227.	0.7	16
54	Neurophysiological correlates of Avolition-apathy in schizophrenia: A resting-EEG microstates study. Neurolmage: Clinical, 2018, 20, 627-636.	2.7	39

#	Article	IF	CITATIONS
55	Untangling the Factors Contributing to Functional Outcome in Schizophrenia—Reply. JAMA Psychiatry, 2018, 75, 754.	11.0	4
56	Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. Acta Psychiatrica Scandinavica, 2018, 138, 253-266.	4.5	44
57	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry,the, 2018, 5, 797-807.	7.4	141
58	31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S50-S51.	4.3	2
59	F111. ELECTROPHYSIOLOGICAL CORRELATES OF AVOLITION-APATHY DOMAIN IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S263-S263.	4.3	0
60	Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases. Schizophrenia Research, 2017, 186, 19-28.	2.0	110
61	Primary, Enduring Negative Symptoms: An Update on Research. Schizophrenia Bulletin, 2017, 43, 730-736.	4.3	85
62	Resting state functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia. European Neuropsychopharmacology, 2017, 27, S67.	0.7	0
63	Neurocognitive Predictors of Social Cognition in Subjects with Schizophrenia and their First-degree Relatives. European Psychiatry, 2017, 41, S40-S40.	0.2	1
64	The Evolution of Negative Symptom Constructs. European Psychiatry, 2017, 41, S14-S15.	0.2	2
65	Applicability and Feasibility of the Italian Version of the Cognitive Remediation Program Circuits: A Pilot Study. European Psychiatry, 2017, 41, s786-s786.	0.2	0
66	Validation of the Italian Version of the "abnormal Bodily Phenomena Questionnaire―in a Sample of Patients with Schizophrenia: Preliminary Data. European Psychiatry, 2017, 41, S80-S80.	0.2	0
67	The Impact of Premorbid Functioning on Outcome Indices in a Large Sample of Italian Patients with Schizophrenia. European Psychiatry, 2017, 41, S96-S96.	0.2	0
68	Effects of chronic antipsychotic treatment on neurophysiological correlates of the auditory oddball task in schizophrenia: A preliminary report from a multicentre study. European Psychiatry, 2017, 41, S192-S192.	0.2	0
69	VTA-insula Connectivity and Avolition in Subjects with Schizophrenia. European Psychiatry, 2017, 41, S57-S57.	0.2	0
70	Functional connectivity of the ventral tegmental area and avolition in schizophrenia: A resting state functional MRI study. European Psychiatry, 2017, 41, S196-S196.	0.2	0
71	Characterization of different subtypes of schizophrenia: Premorbid functioning, neurophysiological differences, functional outcomes. European Psychiatry, 2017, 41, S52.	0.2	0
72	Electrophysiological Correlates of Negative Symptom Domains in Schizophrenia. European Psychiatry, 2017, 41, S96-S97.	0.2	0

#	Article	IF	CITATIONS
73	Disorganization in Schizophrenia: A Resting EEG Study. European Psychiatry, 2017, 41, S100-S100.	0.2	O
74	Cognitive Dysfunctions in the Psychoses and their Impact on Patients' Social Functioning. European Psychiatry, 2017, 41, S48-S48.	0.2	0
75	A Hybrid Effectiveness-implementation Trial of Wellness Self-management Program for Patients with Severe Mental Illness in an Italian Day Hospital Setting. European Psychiatry, 2017, 41, S96-S96.	0.2	0
76	Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. Psychiatry Research, 2017, 256, 359-364.	3.3	49
77	The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 285-294.	3.2	33
78	Resilience in people with schizophrenia. Results from the Italian Network for Research on Psychoses. European Journal of Public Health, 2017, 27, .	0.3	1
79	SoCIAL & Disease and Treatment, 2017, Volume 13, 1947-1956.	2.2	12
80	Negative symptoms domains: pathways to functional outcome in schizophrenia. European Neuropsychopharmacology, 2016, 26, S123.	0.7	0
81	Neurophysiological correlates of negative symptom domains: an auditory oddball study in schizophrenia. European Neuropsychopharmacology, 2016, 26, S506-S507.	0.7	1
82	Electrophysiological mechanisms underlying ERP amplitude reduction in patients with schizophrenia: A time-frequency analysis. European Psychiatry, 2016, 33, S104-S104.	0.2	0
83	The social cognition individualized activities lab: Implementation of a new remediation intervention for social cognition. European Psychiatry, 2016, 33, S567-S567.	0.2	0
84	Neurophysiological correlates of negative symptom domains in patients with schizophrenia. European Psychiatry, 2016, 33, s265-s265.	0.2	0
85	A multicentric study on cognitive functions in a large sample of patients with schizophrenia and their unaffected first-degree relatives. European Psychiatry, 2016, 33, s244-s244.	0.2	0
86	A comprehensive systematic screening protocol for assessment of medical comorbidities in schizophrenia. European Psychiatry, 2016, 33, S574-S574.	0.2	0
87	Relationships between neurocognition, social cognition and functional outcome in schizophrenia. European Psychiatry, 2016, 33, S67-S67.	0.2	1
88	Social cognition in people with schizophrenia: a cluster-analytic approach. Psychological Medicine, 2016, 46, 2717-2729.	4.5	65
89	Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophrenia Research, 2016, 175, 154-160.	2.0	66
90	Relation between EEG source functional connectivity and the negative symptom severity in schizophrenia: a preliminary report from a multicentre study. European Psychiatry, 2016, 33, s246-s246.	0.2	0

#	Article	IF	Citations
91	Avolition in schizophrenia: associations with trait and state anhedonia. European Psychiatry, 2016, 33, s246-s246.	0.2	0
92	The second-generation assessment scales: Brief negative symptom scale and clinical assessment interview for negative symptoms. European Psychiatry, 2016, 33, S70-S70.	0.2	2
93	Reward anticipation and trait anhedonia: An electrophysiological investigation in subjects with schizophrenia. Clinical Neurophysiology, 2016, 127, 2149-2160.	1.5	45
94	Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings. Schizophrenia Research, 2016, 174, 172-176.	2.0	25
95	ls avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. Psychological Medicine, 2015, 45, 1765-1778.	4.5	108
96	Reward Anticipation and Negative Symptoms in Schizophrenia: an Electrophysiological Investigation. European Psychiatry, 2015, 30, 280.	0.2	0
97	Neurobiological background of negative symptoms. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 543-558.	3.2	81
98	The Brief Negative Symptom Scale (BNSS): Independent validation in a large sample of Italian patients with schizophrenia. European Psychiatry, 2015, 30, 641-647.	0.2	114
99	Negative Symptoms in Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2014, 8, 28-35B.	1.4	19
100	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry, 2014, 13, 275-287.	10.4	346
101	The Specific Level of Functioning Scale: Construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. Schizophrenia Research, 2014, 159, 144-150.	2.0	64
102	Electrophysiological Aberrations Associated with Negative Symptoms in Schizophrenia. Current Topics in Behavioral Neurosciences, 2014, 21, 129-156.	1.7	32
103	Physiological Correlates of Positive Symptoms in Schizophrenia. Current Topics in Behavioral Neurosciences, 2014, 21, 103-128.	1.7	13
104	EPA-1469 – Neurocognitive training and functional outcome: is there any evidence of a direct relationship. European Psychiatry, 2014, 29, 1.	0.2	0
105	Neurocognitive individualized training versus social skills individualized training: A randomized trial in patients with schizophrenia. Schizophrenia Research, 2013, 150, 69-75.	2.0	24
106	Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome. Schizophrenia Research, 2013, 147, 157-162.	2.0	148
107	Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology, 2013, 23, 196-204.	0.7	137
108	Impulsiveness in Patients with Bulimia Nervosa: Electrophysiological Evidence of Reduced Inhibitory Control. Neuropsychobiology, 2013, 68, 116-123.	1.9	8

#	Article	IF	Citations
109	Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 37, 264-269.	4.8	30
110	Effects of antipsychotics on cognitive functions: an ERP study in healthy controls. European Psychiatry, 2011, 26, 1267-1267.	0.2	1
111	Perception of body shape in bulimia nervosa: An ERP study. European Psychiatry, 2011, 26, 741-741.	0.2	0
112	Survival from coma induced by an intentional 36-g overdose of extended-release quetiapine. Drug and Chemical Toxicology, 2011, 34, 475-477.	2.3	5
113	Social skills vs. Neurocognitive training in psychotic patients. European Psychiatry, 2011, 26, 1475-1475.	0.2	1
114	Neurocognitive functioning in bulimia nervosa: the role of neuroendocrine, personality and clinical aspects. Psychological Medicine, 2011, 41, 839-848.	4.5	26
115	Social skills and neurocognitive individualized training in schizophrenia: comparison with structured leisure activities. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 305-315.	3.2	47
116	NRG1 and BDNF genes in schizophrenia: An association study in an Italian case-control sample. Psychiatry Research, 2010, 176, 82-84.	3.3	24
117	Evidence-Based Medicine and Electrophysiology in Schizophrenia. Clinical EEG and Neuroscience, 2009, 40, 62-77.	1.7	85
118	Oxytocin receptor polymorphisms and adult attachment style in patients with depression. Psychoneuroendocrinology, 2009, 34, 1506-1514.	2.7	221
119	Mutation analysis of oxytocin gene in individuals with adult separation anxiety. Psychiatry Research, 2009, 168, 87-93.	3.3	21
120	Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study. Schizophrenia Research, 2009, 115, 104-114.	2.0	102
121	Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. Psychiatric Genetics, 2009, 19, 110-111.	1.1	56
122	Cerebral connectivity and psychotic personality traits. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 292-299.	3.2	23
123	Alexithymia and Cognitive Dysfunctions in Patients with Panic Disorder. Psychotherapy and Psychosomatics, 2008, 77, 182-188.	8.8	66
124	ERP changes induced by antipsychotic drugs. European Psychiatry, 2008, 23, S78.	0.2	0
125	Social skills and neurocognitive individualized training in patients with schizophrenia. European Psychiatry, 2008, 23, S137-S138.	0.2	0
126	Cognitive-enhancing effects of aripiprazole: a case report. Clinical Practice and Epidemiology in Mental Health, 2008, 4, 24.	1.2	12

#	Article	IF	Citations
127	Patterns of Structural MRI Abnormalities in Deficit and Nondeficit Schizophrenia. Schizophrenia Bulletin, 2007, 34, 393-401.	4.3	85
128	Induced Gamma Activity and Event-Related Coherence in Schizophrenia. Clinical EEG and Neuroscience, 2007, 38, 96-104.	1.7	57
129	The cortical generators of P3a and P3b: A LORETA study. Brain Research Bulletin, 2007, 73, 220-230.	3.0	210
130	Topographic and tomographic EEG changes after a single oral dose of antipsychotic drugs in healthy young subjects. European Psychiatry, 2007, 22, S160-S161.	0.2	0
131	A psychophysiological investigation of emotional processing in subjects with panic disorder. European Psychiatry, 2007, 22, S289.	0.2	0
132	Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. Schizophrenia Research, 2007, 92, 252-261.	2.0	57
133	Neurocognitive indices of executive hypercontrol in obsessive?compulsive disorder. Acta Psychiatrica Scandinavica, 2007, 115, 380-387.	4.5	34
134	Sources of cortical rhythms in adults during physiological aging: A multicentric EEG study. Human Brain Mapping, 2006, 27, 162-172.	3.6	253
135	Pharmaco-EEG in Psychiatry. Clinical EEG and Neuroscience, 2006, 37, 81-98.	1.7	59
136	Hemispheric lateralization patterns and psychotic experiences in healthy subjects. Psychiatry Research - Neuroimaging, 2005, 139, 141-154.	1.8	16
137	EEG microstate duration and syntax in acute, medication-na \tilde{A} -ve, first-episode schizophrenia: a multi-center study. Psychiatry Research - Neuroimaging, 2005, 138, 141-156.	1.8	316
138	Catechol-O-Methyltransferase Val ¹⁵⁸ Met Polymorphism in Schizophrenia: Associations with Cognitive and Motor Impairment. Neuropsychobiology, 2005, 52, 83-89.	1.9	51
139	Modified nutritional counselling to increase motivation to treatment in anorexia nervosa. European Psychiatry, 2005, 20, 186-187.	0.2	48
140	Decrease of functional coupling between left and right auditory cortices during dichotic listening: An electroencephalography study. Neuroscience, 2005, 136, 323-332.	2.3	21
141	COMT Val158Met and BDNF C270T polymorphisms in schizophrenia: a case-control study. Schizophrenia Research, 2005, 73, 27-30.	2.0	42
142	Selected E-ISNR 2004 Conference Presentation Abstracts. Journal of Neurotherapy, 2005, 9, 103-108.	0.9	0
143	Inhibition of auditory cortical responses to ipsilateral stimuli during dichotic listening: evidence from magnetoencephalography. European Journal of Neuroscience, 2004, 19, 2329-2336.	2.6	90
144	Executive hypercontrol in obsessive–compulsive disorder: electrophysiological and neuropsychological indices. Clinical Neurophysiology, 2004, 115, 1340-1348.	1.5	60

#	Article	IF	CITATIONS
145	Neurocognitive functioning in subjects with eating disorders: the influence of neuroactive steroids. Biological Psychiatry, 2003, 53, 921-927.	1.3	50
146	Historical, Psychopathological, Neurological, and Neuropsychological Aspects of Deficit Schizophrenia: A Multicenter Study. American Journal of Psychiatry, 2002, 159, 983-990.	7.2	127
147	Psychophysiology in psychiatry: new perspectives in the study of mental disorders. World Psychiatry, 2002, 1, 166-8.	10.4	4
148	Brain electrical microstates in subjects with panic disorder. Brain Research Bulletin, 2001, 54, 427-435.	3.0	15
149	Nramp1 gene affects selective early steps in macrophage-mediated anti-cryptococcal defense. Medical Microbiology and Immunology, 2001, 189, 209-216.	4.8	7
150	Brain Hemispheric Organization, Anxiety, and Psychoses. CNS Spectrums, 2000, 5, 58-69.	1.2	76
151	Emotions, Brain Development, and Psychopathologic Vulnerability. CNS Spectrums, 2000, 5, 44-48.	1.2	13
152	S21.02 Cognitive dysfunctions in psychotic patients: Relationship with symptoms and antipsychotic treatment. European Psychiatry, 2000, 15, 252s-252s.	0.2	0
153	â€~Simple schizophrenia': a controlled MRI and clinical/neuropsychological study. Psychiatry Research - Neuroimaging, 1999, 91, 175-184.	1.8	16
154	Hemispheric asymmetry and psychopathological dimensions in drug-free patients with schizophrenia. International Journal of Psychophysiology, 1999, 34, 293-301.	1.0	38
155	EEG mapping before and after antipsychotic treatment in chronic and first-episode schizophrenics. European Psychiatry, 1998, 13, 197S-197S.	0.2	0
156	Quantitative EEG in Psychiatry: From Research to Clinical Applications. European Psychiatry, 1997, 12, 105s-105s.	0.2	0
157	Quantitative EEG reactivity to neuroleptic challenge in first-episode and chronic schizophrenics. Biological Psychiatry, 1997, 42, 64S.	1.3	1
158	Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. Psychiatry Research - Neuroimaging, 1996, 67, 113-122.	1.8	24
159	Influence of Moclobemide on Cognitive Functions of Nine Depressed Patients: Pilot Trial with Neurophysiological and Neuropsychological Indices. Neuropsychobiology, 1996, 33, 48-54.	1.9	10
160	Neuropsychological Slowness in Obsessive–Compulsive Patients. British Journal of Psychiatry, 1995, 167, 394-398.	2.8	78
161	Levosulpiride: a review of its clinical use in psychiatry. Pharmacological Research, 1995, 31, 95-101.	7.1	40
162	QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. Biological Psychiatry, 1994, 35, 367-374.	1.3	50

#	Article	IF	CITATIONS
163	Haloperidol-Induced Changes of Computerized Electroencephalogram Topography in Drug-Free Schizophrenic Patients., 1993,, 245-250.		O
164	Computerized EEG topography findings in schizophrenic patients before and after haloperidol treatment. International Journal of Psychophysiology, 1992, 13, 283-290.	1.0	35
165	Lateralization patterns of event-related potential and performance indices in schizophrenia: relationship to clinical state and neuroleptic treatment. International Journal of Psychophysiology, 1991, 10, 225-230.	1.0	13
166	Dynamic brain mapping methodology and application. International Journal of Psychophysiology, 1991, 10, 281-291.	1.0	21
167	CEEG mapping in drug-free schizophrenics. Schizophrenia Research, 1991, 6, 15-23.	2.0	56
168	C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment. European Neuropsychopharmacology, 1990, 1, 51-54.	0.7	15
169	Discrimination of Mode of Action of Anxiolytics using an Integrated Computer Data Bank and Dynamic Brain Mapping (CNS Effects of Diazepam and Lorazepam). International Clinical Psychopharmacology, 1989, 4, 273-284.	1.7	9
170	Lateralization patterns of verbal stimuli processing assessed by reaction time and event-related potentials in schizophrenic patients. International Journal of Psychophysiology, 1988, 6, 167-176.	1.0	19
171	Conditional Associative Learning in Drug-Free Schizophrenic Patients. Neuropsychobiology, 1987, 17, 30-34.	1.9	27